<br>        Inclusion criteria :<br><br>        I 01. Diagnosis of histologically or cytologically proven prostate adenocarcinoma, that was<br>        resistant to hormone therapy and previously treated with a docetaxel-containing regimen.<br><br>        I 02. Participant must had either measurable or non-measurable disease. I 03. Received<br>        prior castration by orchiectomy and/or Luteinizing Hormone-Releasing Hormone (LH-RH)<br>        agonist with or without antiandrogen, antiandrogen withdrawal, monotherapy with<br>        estramustine, or other hormonal agents.<br><br>        I 04. Life expectancy > 6 months. I 05. Eastern Cooperative Oncology Group (ECOG)<br>        performance status (PS) 0 - 2 (i.e, participant must be ambulatory, capable of all<br>        self-care, and up and about more than 50% of waking hours).<br><br>        I 06. Age =18 years (or country's legal age of majority if the legal age was > 18 years).<br><br>        Exclusion criteria:<br><br>        E 01. Previous treatment with mitoxantrone or cabazitaxel. E 02. Prior isotope therapy or<br>        radiotherapy to =30% of bone marrow. In case of prior isotope therapy 12 weeks must had<br>        elapsed prior to first study drug administration.<br><br>        E 03. Adverse events (excluding alopecia and those listed in the specific exclusion<br>        criteria) from any prior anticancer therapy of grade >1(National Cancer Institute Common<br>        Terminology Criteria [NCI CTCAE] v4.03) at the time of randomization.<br><br>        E 04. Prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks<br>        prior to enrollment in the study.<br><br>        E 05. Prior malignancy. Adequately treated basal cell or squamous cell skin or superficial<br>        (pTis, pTa, and pT1) bladder cancer were allowed, as well as any other cancer for which<br>        chemotherapy had been completed = 5 years ago and from which the participant had been<br>        disease-free for = 5 years.<br><br>        E 06. Participation in another clinical trial and any concurrent treatment with any<br>        investigational drug within 30 days prior to randomization.<br><br>        E 07. Known brain or leptomeningeal involvement. E 08. Other concurrent serious illness or<br>        medical conditions. E 09. Uncontrolled cardiac arrhythmias, angina pectoris, and/or<br>        hypertension. History of congestive heart failure (NYHA III or IV) or myocardial infarction<br>        within last 6 months was also not allowed.<br><br>        E 10. Any severe acute or chronic medical condition which could impair the ability of the<br>        participant to participate to the study or to comply with the study procedures or interfere<br>        with interpretation of study results.<br><br>        E 11. Absence of signed and dated Institutional Review Board (IRB)-approved participant<br>        informed consent form prior to enrollment into the study.<br><br>        E 12. Participants with reproductive potential who did not agree to use accepted and<br>        effective method of contraception during the study treatment period. The definition of<br>        effective method of contraception was based on the Investigator's judgment. Participant's<br>        Partners of childbearing potential (unless surgically sterile, post menopausal or for<br>        another reason had no chance of becoming pregnant) not protected by highly effective<br>        contraceptive method of birth control as defined for contraception in the Informed Consent<br>        Form and /or in a local protocol addendum.<br><br>        E 13. History of hypersensitivity to docetaxel, or polysorbate 80. E 14. Inadequate organ<br>        and bone marrow function. E 15. Contraindications to the use of corticosteroid treatment. E<br>        16. Symptomatic peripheral neuropathy grade > 2 (NCI CTCAE v.4.03).<br><br>        The above information was not intended to contain all considerations relevant to a<br>        participant's potential participation in a clinical trial.<br>      ;<br>        Inclusion criteria :<br><br>        I 01. Diagnosis of histologically or cytologically proven prostate adenocarcinoma, that was<br>        resistant to hormone therapy and previously treated with a docetaxel-containing regimen.<br><br>        I 02. Participant must had either measurable or non-measurable disease. I 03. Received<br>        prior castration by orchiectomy and/or Luteinizing Hormone-Releasing Hormone (LH-RH)<br>        agonist with or without antiandrogen, antiandrogen withdrawal, monotherapy with<br>        estramustine, or other hormonal agents.<br><br>        I 04. Life expectancy > 6 months. I 05. Eastern Cooperative Oncology Group (ECOG)<br>        performance status (PS) 0 - 2 (i.e, participant must be ambulatory, capable of all<br>        self-care, and up and about more than 50% of waking hours).<br><br>        I 06. Age =18 years (or country's legal age of majority if the legal age was > 18 years).<br><br>        Exclusion criteria:<br><br>        E 01. Previous treatment with mitoxantrone or cabazitaxel. E 02. Prior isotope therapy or<br>        radiotherapy to =30% of bone marrow. In case of prior isotope therapy 12 weeks must had<br>        elapsed prior to first study drug administration.<br><br>        E 03. Adverse events (excluding alopecia and those listed in the specific exclusion<br>        criteria) from any prior anticancer therapy of grade >1(National Cancer Institute Common<br>        Terminology Criteria [NCI CTCAE] v4.03) at the time of randomization.<br><br>        E 04. Prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks<br>        prior to enrollment in the study.<br><br>        E 05. Prior malignancy. Adequately treated basal cell or squamous cell skin or superficial<br>        (pTis, pTa, and pT1) bladder cancer were allowed, as well as any other cancer for which<br>        chemotherapy had been completed = 5 years ago and from which the participant had been<br>        disease-free for = 5 years.<br><br>        E 06. Participation in another clinical trial and any concurrent treatment with any<br>        investigational drug within 30 days prior to randomization.<br><br>        E 07. Known brain or leptomeningeal involvement. E 08. Other concurrent serious illness or<br>        medical conditions. E 09. Uncontrolled cardiac arrhythmias, angina pectoris, and/or<br>        hypertension. History of congestive heart failure (NYHA III or IV) or myocardial infarction<br>        within last 6 months was also not allowed.<br><br>        E 10. Any severe acute or chronic medical condition which could impair the ability of the<br>        participant to participate to the study or to comply with the study procedures or interfere<br>        with interpretation of study results.<br><br>        E 11. Absence of signed and dated Institutional Review Board (IRB)-approved participant<br>        informed consent form prior to enrollment into the study.<br><br>        E 12. Participants with reproductive potential who did not agree to use accepted and<br>        effective method of contraception during the study treatment period. The definition of<br>        effective method of contraception was based on the Investigator's judgment. Participant's<br>        Partners of childbearing potential (unless surgically sterile, post menopausal or for<br>        another reason had no chance of becoming pregnant) not protected by highly effective<br>        contraceptive method of birth control as defined for contraception in the Informed Consent<br>        Form and /or in a local protocol addendum.<br><br>        E 13. History of hypersensitivity to docetaxel, or polysorbate 80. E 14. Inadequate organ<br>        and bone marrow function. E 15. Contraindications to the use of corticosteroid treatment. E<br>        16. Symptomatic peripheral neuropathy grade > 2 (NCI CTCAE v.4.03).<br><br>        The above information was not intended to contain all considerations relevant to a<br>        participant's potential participation in a clinical trial.<br>      ;<br>        Inclusion criteria :<br><br>        I 01. Diagnosis of histologically or cytologically proven prostate adenocarcinoma, that was<br>        resistant to hormone therapy and previously treated with a docetaxel-containing regimen.<br><br>        I 02. Participant must had either measurable or non-measurable disease. I 03. Received<br>        prior castration by orchiectomy and/or Luteinizing Hormone-Releasing Hormone (LH-RH)<br>        agonist with or without antiandrogen, antiandrogen withdrawal, monotherapy with<br>        estramustine, or other hormonal agents.<br><br>        I 04. Life expectancy > 6 months. I 05. Eastern Cooperative Oncology Group (ECOG)<br>        performance status (PS) 0 - 2 (i.e, participant must be ambulatory, capable of all<br>        self-care, and up and about more than 50% of waking hours).<br><br>        I 06. Age =18 years (or country's legal age of majority if the legal age was > 18 years).<br><br>        Exclusion criteria:<br><br>        E 01. Previous treatment with mitoxantrone or cabazitaxel. E 02. Prior isotope therapy or<br>        radiotherapy to =30% of bone marrow. In case of prior isotope therapy 12 weeks must had<br>        elapsed prior to first study drug administration.<br><br>        E 03. Adverse events (excluding alopecia and those listed in the specific exclusion<br>        criteria) from any prior anticancer therapy of grade >1(National Cancer Institute Common<br>        Terminology Criteria [NCI CTCAE] v4.03) at the time of randomization.<br><br>        E 04. Prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks<br>        prior to enrollment in the study.<br><br>        E 05. Prior malignancy. Adequately treated basal cell or squamous cell skin or superficial<br>        (pTis, pTa, and pT1) bladder cancer were allowed, as well as any other cancer for which<br>        chemotherapy had been completed = 5 years ago and from which the participant had been<br>        disease-free for = 5 years.<br><br>        E 06. Participation in another clinical trial and any concurrent treatment with any<br>        investigational drug within 30 days prior to randomization.<br><br>        E 07. Known brain or leptomeningeal involvement. E 08. Other concurrent serious illness or<br>        medical conditions. E 09. Uncontrolled cardiac arrhythmias, angina pectoris, and/or<br>        hypertension. History of congestive heart failure (NYHA III or IV) or myocardial infarction<br>        within last 6 months was also not allowed.<br><br>        E 10. Any severe acute or chronic medical condition which could impair the ability of the<br>        participant to participate to the study or to comply with the study procedures or interfere<br>        with interpretation of study results.<br><br>        E 11. Absence of signed and dated Institutional Review Board (IRB)-approved participant<br>        informed consent form prior to enrollment into the study.<br><br>        E 12. Participants with reproductive potential who did not agree to use accepted and<br>        effective method of contraception during the study treatment period. The definition of<br>        effective method of contraception was based on the Investigator's judgment. Participant's<br>        Partners of childbearing potential (unless surgically sterile, post menopausal or for<br>        another reason had no chance of becoming pregnant) not protected by highly effective<br>        contraceptive method of birth control as defined for contraception in the Informed Consent<br>        Form and /or in a local protocol addendum.<br><br>        E 13. History of hypersensitivity to docetaxel, or polysorbate 80. E 14. Inadequate organ<br>        and bone marrow function. E 15. Contraindications to the use of corticosteroid treatment. E<br>        16. Symptomatic peripheral neuropathy grade > 2 (NCI CTCAE v.4.03).<br><br>        The above information was not intended to contain all considerations relevant to a<br>        participant's potential participation in a clinical trial.<br>      ;<br>        Inclusion criteria :<br><br>        I 01. Diagnosis of histologically or cytologically proven prostate adenocarcinoma, that was<br>        resistant to hormone therapy and previously treated with a docetaxel-containing regimen.<br><br>        I 02. Participant must had either measurable or non-measurable disease. I 03. Received<br>        prior castration by orchiectomy and/or Luteinizing Hormone-Releasing Hormone (LH-RH)<br>        agonist with or without antiandrogen, antiandrogen withdrawal, monotherapy with<br>        estramustine, or other hormonal agents.<br><br>        I 04. Life expectancy > 6 months. I 05. Eastern Cooperative Oncology Group (ECOG)<br>        performance status (PS) 0 - 2 (i.e, participant must be ambulatory, capable of all<br>        self-care, and up and about more than 50% of waking hours).<br><br>        I 06. Age =18 years (or country's legal age of majority if the legal age was > 18 years).<br><br>        Exclusion criteria:<br><br>        E 01. Previous treatment with mitoxantrone or cabazitaxel. E 02. Prior isotope therapy or<br>        radiotherapy to =30% of bone marrow. In case of prior isotope therapy 12 weeks must had<br>        elapsed prior to first study drug administration.<br><br>        E 03. Adverse events (excluding alopecia and those listed in the specific exclusion<br>        criteria) from any prior anticancer therapy of grade >1(National Cancer Institute Common<br>        Terminology Criteria [NCI CTCAE] v4.03) at the time of randomization.<br><br>        E 04. Prior surgery, radiation, chemotherapy, or other anti-cancer therapy within 4 weeks<br>        prior to enrollment in the study.<br><br>        E 05. Prior malignancy. Adequately treated basal cell or squamous cell skin or superficial<br>        (pTis, pTa, and pT1) bladder cancer were allowed, as well as any other cancer for which<br>        chemotherapy had been completed = 5 years ago and from which the participant had been<br>        disease-free for = 5 years.<br><br>        E 06. Participation in another clinical trial and any concurrent treatment with any<br>        investigational drug within 30 days prior to randomization.<br><br>        E 07. Known brain or leptomeningeal involvement. E 08. Other concurrent serious illness or<br>        medical conditions. E 09. Uncontrolled cardiac arrhythmias, angina pectoris, and/or<br>        hypertension. History of congestive heart failure (NYHA III or IV) or myocardial infarction<br>        within last 6 months was also not allowed.<br><br>        E 10. Any severe acute or chronic medical condition which could impair the ability of the<br>        participant to participate to the study or to comply with the study procedures or interfere<br>        with interpretation of study results.<br><br>        E 11. Absence of signed and dated Institutional Review Board (IRB)-approved participant<br>        informed consent form prior to enrollment into the study.<br><br>        E 12. Participants with reproductive potential who did not agree to use accepted and<br>        effective method of contraception during the study treatment period. The definition of<br>        effective method of contraception was based on the Investigator's judgment. Participant's<br>        Partners of childbearing potential (unless surgically sterile, post menopausal or for<br>        another reason had no chance of becoming pregnant) not protected by highly effective<br>        contraceptive method of birth control as defined for contraception in the Informed Consent<br>        Form and /or in a local protocol addendum.<br><br>        E 13. History of hypersensitivity to docetaxel, or polysorbate 80. E 14. Inadequate organ<br>        and bone marrow function. E 15. Contraindications to the use of corticosteroid treatment. E<br>        16. Symptomatic peripheral neuropathy grade > 2 (NCI CTCAE v.4.03).<br><br>        The above information was not intended to contain all considerations relevant to a<br>        participant's potential participation in a clinical trial.<br>